Cholinergic System Dysfunction in DLB — Mechanisms and Therapeutic Restoration

🧫 Experiment Protocol ClinicalAlzheimer's DiseaseDLBhumanproposed

# Cholinergic System Dysfunction in DLB — Mechanisms and Therapeutic Restoration ## Background and Rationale Clinical trial testing whether muscarinic M1 receptor-selective agonism provides superior cognitive benefit in DLB compared to current cholinesterase inhibitors, by directly targeting the post-synaptic receptor rather than modulating pre-synaptic acetylcholine availability. **Protocol**: Phase 2 RCT, 200 DLB patients (McKeith criteria, MMSE 15-26), randomized 1:1:1: (A) HTL0018318 (M1-selective agonist, 10mg BID), (B) donepezil 10mg QD (active comparator), (C) placebo. Duration: 24 weeks. Assessments: CDR-SB, MMSE, NPI (neuropsychiatric inventory for hallucinations/fluctuations), DaT-SPECT at baseline, cholinergic PET (11C-MP4A) at baseline and 24 weeks in a substudy (n=60), polysomnography for REM sleep behavior disorder, EEG for cognitive fluctuation quantification. **Primary Outcome**: Change in CDR-SB at 24 weeks, M1 agonist vs. placebo. **Key Secondary**: NPI hallucination subscale improvement, cognitive fluctuation frequency (EEG), RBD severity. **Success Criteria**: CDR-SB improvement >1.0 points vs. placebo, plus NPI improvement >3 points. **Safety**: QTc monitoring (muscarinic GI effects), seizure risk assessment. **Expected Timeline**: 2.5 years. **Estimated Cost**: $25M. This experiment directly tests predictions arising from the following hypotheses: - **SASP-Mediated Cholinergic Synapse Disruption** - **Gamma entrainment therapy to restore hippocampal-cortical synchrony** - **Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation** - **Prefrontal sensory gating circuit restoration via PV interneuron enhancement** ## Experimental Protocol **Phase 1: Patient Recruitment and Baseline Assessment (Months 1-3)** • Recruit 120 participants: 40 DLB patients, 40 Alzheimer's disease patients, 40 age-matched healthy controls • Inclusion criteria: DLB patients meeting consensus criteria, MMSE 15-26, stable medications for 4 weeks • Exclusion criteria: other neurodegenerative diseases, severe psychiatric conditions, contraindications to PET/MRI • Obtain informed consent and complete baseline cognitive assessment (MoCA, MMSE, DLB-specific scales) • Collect demographic data, medication history, and clinical severity ratings **Phase 2: Neuroimaging and Biomarker Collection (Months 2-6)** • Perform [18F]FEOBV PET imaging to assess vesicular acetylcholine transporter (VAChT) density • Conduct structural MRI with DTI sequences to evaluate white matter integrity • Collect CSF samples for acetylcholine, choline acetyltransferase, and α-synuclein measurements • Obtain blood samples for plasma cholinergic biomarkers and genetic analysis (APOE, COMT) • Complete autonomic function testing including heart rate variability and pupillometry **Phase 3: Cholinergic Challenge Testing (Months 4-8)** • Administer physostigmine challenge test (0.5-1.0 mg IV) with continuous monitoring • Measure cognitive response using attention and executive function batteries pre/post challenge • Assess pupillary light reflex changes and autonomic responses • Document adverse events and treatment responses over 4-hour observation period • Repeat testing after 2-week washout period for reliability assessment **Phase 4: Therapeutic Intervention Trial (Months 6-18)** • Randomize DLB patients to rivastigmine (6-12 mg/day) vs placebo in double-blind design • Monthly clinical assessments using Neuropsychiatric Inventory and DLB rating scales • Quarterly cognitive testing and cholinergic biomarker measurements • Monitor for side effects and adjust dosing based on tolerability • Complete follow-up neuroimaging at 6 and 12 months post-treatment initiation **Phase 5: Data Analysis and Validation (Months 16-24)** • Perform statistical analysis comparing cholinergic markers between groups using ANOVA • Correlate neuroimaging findings with clinical symptoms and biomarker levels • Validate predictive models for treatment response using machine learning approaches • Conduct longitudinal analysis of cholinergic decline patterns in DLB vs AD • Prepare comprehensive dataset for external validation studies ## Expected Outcomes 1. **Cholinergic Deficit Quantification**: DLB patients will show 35-45% reduction in VAChT binding compared to controls (p<0.001), with greater deficits than AD patients in posterior cortical regions and thalamus. 2. **Biomarker Profile Differences**: CSF acetylcholine levels will be 40-50% lower in DLB vs controls (p<0.001), with distinct α-synuclein/cholinergic marker correlation patterns (r>0.6) differentiating DLB from AD. 3. **Physostigmine Response Pattern**: DLB patients will demonstrate enhanced cognitive improvement (Cohen's d=0.8-1.2) following physostigmine challenge compared to AD patients, particularly in attention and executive domains. 4. **Treatment Efficacy**: Rivastigmine-treated DLB patients will show 25-35% improvement in NPI scores and 15-20% improvement in cognitive measures compared to placebo group (effect size d>0.6). 5. **Neuroimaging-Clinical Correlations**: VAChT binding density will correlate strongly with cognitive fluctuation severity (r=0.7-0.8) and predict treatment response with AUC>0.75 in ROC analysis. 6. **Autonomic-Cholinergic Relationships**: Heart rate variability and pupillary responses will correlate significantly with cholinergic biomarkers (r>0.5), establishing peripheral markers of central cholinergic dysfunction. ## Success Criteria • **Statistical Significance**: Primary endpoints achieve p<0.05 with Bonferroni correction for multiple comparisons, and effect sizes >0.6 for key cholinergic measures • **Sample Size Achievement**: Maintain >85% retention rate with minimum 34 evaluable patients per group for adequate statistical power (80% power, α=0.05) • **Biomarker Validation**: Cholinergic biomarkers demonstrate test-retest reliability >0.8 and show significant group differences with non-overlapping 95% confidence intervals • **Clinical Relevance**: Treatment effects show clinically meaningful improvements (>3 points on NPI, >2 points on cognitive scales) in >60% of treated patients • **Imaging Quality Standards**: >90% of PET scans meet quality criteria with successful quantification of VAChT binding in target regions of interest • **Safety Profile**: Adverse event rate <15% for serious events related to study procedures, with no unexpected safety signals requiring study modification

Source: wiki

🧫 Experiment Extras

🔴 Alzheimer's Disease 🧠 Neurodegeneration

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found